#None #Securities Fraud #Medpace Holdings #Jesse Geiger

Medpace Holdings Inc. Faces Class Action

Overview of the Allegations

In a significant legal development, Medpace Holdings Inc. is under scrutiny following a securities fraud lawsuit initiated by Levi & Korsinsky, LLP. The firm's latest alert emphasizes that Jesse J. Geiger, the President of Medpace, has been named in a class action suit that alleges egregious misleading disclosures during key financial reporting periods.

The lawsuit covers purchases made between April 22, 2025, and February 9, 2026, and aims to hold Geiger accountable for the alleged misrepresentation of the company’s financial health. This legal action comes in the wake of disappointing revenue forecasts that led to a significant decline of more than 15.9% in the value of Medpace shares, dropping from an initial peak of $84.30 per share.

Key Details Surrounding the Class Action

According to court documents, the decline in stock value was precipitated by the company's Q4 2025 report, which projected a suboptimal book-to-bill ratio of 1.04x compared to prior guidance of 1.15x. This discrepancy not only blindsided investors but also highlighted concerning trends within the company's operational metrics.

Geiger, who has had direct communication with investors and analysts during earnings calls, allegedly presented an overly optimistic view of Medpace’s backlog and revenue forecasts. For instance, data released by the company on April 22, 2025, indicated a revenue of $558.6 million and a net book-to-bill ratio of 0.9. Conversely, by October 23, 2025, during another earnings call, he reported an upswing in revenue to $659.9 million, which further solidified investor confidence—momentarily.

Yet, when revealing Q4 2025 details on February 10, 2026, Geiger reported a sharp drop to a book-to-bill ratio of 1.04 despite achieving a revenue of $708.5 million, indicating that the company's growth trajectory was not as robust as previously suggested.

The Role of Geiger in Misleading Disclosures

The lawsuit posits that Geiger had significant control over Medpace's public disclosures, whether they be SEC filings, press releases, or analyst presentations. This control enabled him to present an overly favorable narrative around the company's performance while failing to disclose crucial information about increasing backlog cancellations and the concentrated risks in its metabolic studies.

Among the allegations is a claim that Geiger was aware, or should have been aware, of several concerning trends:

• - Backlog cancellations were increasing, particularly in metabolic trials.
• - The earlier projected book-to-bill ratio of 1.15x for 2025 was becoming increasingly unrealistic.
• - Revenue growth heavily relied on a narrow range of metabolic studies rather than being diversified, as portrayed to investors.
• - The therapeutic concentration of the pre-backlog pipeline presented significant risks that could affect future bookings.

Consequences and Future Outlook

Geiger's position and involvement in the alleged misleading disclosures raise critical questions about accountability among corporate officers. Joseph E. Levi, a principal at Levi & Korsinsky, noted, "Individuals who certify financial disclosures bear personal responsibility for accuracy. When executives publicly present financial results, they should be ready to accept accountability."

The deadline for potential lead plaintiffs to step forward in this unfolding situation is set for June 8, 2026. Investors who suffered losses during the aforementioned period are encouraged to assess their eligibility for participation in the class action.

For those who sold their shares, eligibility is based on purchase dates rather than current holdings. Furthermore, the class action is structured on a contingency basis, meaning no upfront fees are required, which lowers the barrier for investors to seek recompense.

Conclusion

The Medpace Holdings case reflects the increasing scrutiny surrounding corporate governance and securities disclosure practices. As the legal proceedings unfold, stakeholders remain vigilant, anticipating the outcomes as they seek to ensure justice and accountability in the corporate sector.